Novacyt S.A.: Launch of Respiratory Test Panel
27 Agosto 2020 - 8:00AM
Business Wire
New test differentiates COVID-19 from common
winter diseases
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the
"Company" or the “Group”), an international specialist in clinical
diagnostics, announces the launch of its CE-Mark approved
polymerase chain reaction (PCR) respiratory test panel,
Winterplex™.
On 27 July 2020, Novacyt announced the development of a
respiratory test panel, which includes its high-performance
COVID-19 PCR test. The Winterplex™ test panel includes two gene
targets specific to COVID-19, as well as gene targets for influenza
A&B and respiratory syncytial virus (RSV). Clinical trial data
demonstrated 100% specificity and between 96% and 100% sensitivity
across the panel.
There remains a challenge for healthcare providers in
differentiating COVID-19 from other respiratory diseases,
particularly during a seasonal flu outbreak, due to patients
presenting with similar symptoms. This is driving the requirement
for the development of respiratory test panels that are able to
diagnose and distinguish the difference between types of flu and
COVID-19.
The test panel is designed to be used on any open PCR platform,
including the Company’s rapid, portable q32 instrument. The Company
is using its existing manufacturing capacity to produce the test
panel and believes it can meet the expected global demand for the
product. The test panel is expected to drive significant
incremental revenue for the Company.
Graham Mullis, Group CEO of Novacyt, commented: “Novacyt
has established itself as a pioneer in COVID-19 diagnostics through
the rapid development and success of its COVID-19 PCR test and the
launch of Winterplex™ is another example of this innovative
approach. We believe Winterplex™ is one of the world’s first
approved respiratory test panels that can differentiate between
COVID-19 and other common respiratory diseases. The test panel is a
key addition to our COVID-19 product portfolio to support
healthcare providers as we approach flu season in the Northern
hemisphere.”
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
About Novacyt Group The Novacyt Group is an international
diagnostics business generating an increasing portfolio of in vitro
and molecular diagnostic tests. Its core strengths lie in
diagnostics product development, commercialisation, contract design
and manufacturing. The Company's lead business units comprise of
Primerdesign and Lab21 Products, supplying an extensive range of
high-quality assays and reagents worldwide. The Group directly
serves microbiology, haematology and serology markets as do its
global partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200826005781/en/
Novacyt SA Graham Mullis, Chief Executive Officer Anthony
Dyer, Chief Financial Officer +44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470
0470
FTI Consulting (International) Victoria Foster Mitchell /
Mary Whittow +44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France) Arnaud de Cheffontaines +33
(0)147 03 69 47 arnaud.decheffontaines@fticonsulting.com
Grafico Azioni Novacyt (EU:ALNOV)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Novacyt (EU:ALNOV)
Storico
Da Apr 2023 a Apr 2024